Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

333
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
333
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between CMR-derived pulmonary artery pulse wave velocity and pulmonary risk factors: the multi-ethnic study of atherosclerosis COPD study.

Magnetic resonance imaging·2026
Same author

Microglial clonal dynamics and the impact of clonal hematopoiesis in autologously transplanted rhesus macaques.

Cell reports·2026
Same author

Myelodysplastic Syndromes in VEXAS.

Blood advances·2026
Same author

Restricting glycine uptake with bitopertin improves erythropoiesis in preclinical models of Diamond-Blackfan anemia.

Blood. Red cells & iron·2026
Same author

How I utilize somatic alterations in the diagnosis, risk stratification, and therapy of hypocellular bone marrow failure.

Blood·2026
Same author

Clonal Selection and Evolution after Treatment of Severe Aplastic Anemia.

NEJM evidence·2026

Related Experiment Video

Updated: Jul 9, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.5K

Granulocyte transfusions in severe aplastic anemia.

Roma V Rajput1, Vaani Shah2, Ruba N Shalhoub3

  • 1Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD. Roma.Rajput@nih.gov.

Haematologica
|December 7, 2023
PubMed
Summary

Granulocyte transfusions (GT) in severe aplastic anemia (SAA) patients showed a 50% overall survival from initial transfusion. GT may improve survival by bridging patients to hematopoietic stem cell transplant (HSCT).

More Related Videos

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

7.9K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.6K

Related Experiment Videos

Last Updated: Jul 9, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.5K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

7.9K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.6K

Area of Science:

  • Hematology
  • Transfusion Medicine

Background:

  • Severe aplastic anemia (SAA) patients face high infection-related morbidity and mortality.
  • The role of granulocyte transfusions (GT) in managing SAA infections requires further characterization.

Purpose of the Study:

  • To evaluate the impact of granulocyte transfusions (GT) on survival outcomes in patients with severe aplastic anemia (SAA).
  • To assess clinical response and complications associated with GT in SAA patients.

Main Methods:

  • Retrospective analysis of 28 SAA patients undergoing 30 GT courses.
  • Primary outcomes included overall survival (OS), survival to discharge, and receipt of hematopoietic stem cell transplant (HSCT).
  • Secondary outcomes assessed clinical response at 7 and 30 days using a scoring system.

Main Results:

  • Overall survival from initial GT was 50%, with 39% alive at last follow-up (median 551 days).
  • Sixty-four percent of patients survived to hospital discharge; 86% awaiting HSCT received it.
  • Patients with infection response at 30 days had significantly better OS (P=0.0004).

Conclusions:

  • GT in SAA patients with infection improvement or stabilization may impact survival.
  • While overall survival remains poor and alloimmunization can occur, GT can serve as a bridge to HSCT.
  • GT may be a valuable supportive therapy for SAA patients awaiting definitive treatment.